Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

類似資料

• Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
  著者:: Jabbour, Elias, 等
  出版事項: (2011)
• Acute myeloid leukemia: current progress and future directions
  著者:: Kantarjian, Hagop, 等
  出版事項: (2021)
• Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
  著者:: Jabbour, Elias, 等
  出版事項: (2008)
• The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
  著者:: Jabbour, Elias, 等
  出版事項: (2011)
• Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast-Phase Chronic Myeloid Leukemia
  著者:: Jabbour, Elias, 等
  出版事項: (2012)